Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Hematology
•
Systemic lupus erythematosus
•
JAK Inhibitors
Is there any role for ruxolitinib in the management of secondary autoimmune myelofibrosis in patients with SLE?
Related Questions
How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?
Is there a role for voclosporin in non-renal lupus?
What is your approach to RSV vaccination in immunocompromised patients?
Would you consider utilizing a TNF-inhibitor in a patient with RA/SLE overlap who has already tried methotrexate, hydroxychloroquine, and abatacept?
Is there practical utility from obtaining CSF autoantibodies in patients with suspected neuropsychiatric systemic lupus erythematosus?
What is your workup for CSF studies when evaluating for possible CNS Lupus?
What is your approach to evaluating a patient with known rheumatologic disease and elevated free kappa:lambda ratio, but no evidence of monoclonal immunoglobulins?
How do you monitor patients with cutaneous lupus for progression to SLE?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
